Unlocking Biotechnology Growth in the Middle East and Africa: From Emerging Potential to Global Impact

By Nasser Al-Kaabi, Head – Investment Facilitation, Invest Qatar 

Biotechnology is rapidly emerging as one of the defining industries of the 21st century. From developing life-saving therapies and strengthening food security to advancing sustainable manufacturing and addressing environmental challenges, its impact extends far beyond the laboratory. As nations seek to build more resilient, knowledge-based economies, biotechnology has become a strategic priority, driving innovation, attracting investment and shaping the future of the global bioeconomy. 

The sector’s economic significance continues to accelerate. The global biotechnology market is projected to grow from USD 1.38 trillion in 2025 to USD 4.33 trillion by 2034, reflecting a compound annual growth rate (CAGR) of 13.6%. 

Increasingly, policymakers recognise that leadership in biotechnology is not merely a scientific ambition but an economic necessity for competitiveness, resilience and long-term prosperity. 

Why the Middle East and Africa Matter 

While North America remains the largest biotechnology market and Asia-Pacific is expected to experience the fastest growth, the Middle East and Africa (MEA) are emerging as increasingly important contributors. The region is projected to grow from USD 51.5 billion in 2025 to USD 125.9 billion by 2034, representing a CAGR of 10.5%, underscoring the region's growing importance within the global biotechnology landscape. 

This momentum is being driven by rising healthcare demand, increased investment in research and development, a growing focus on food security and sustainability, and efforts to diversify economies beyond traditional sectors. The question is no longer whether MEA will participate in the biotechnology economy, but how countries can build the ecosystems needed to translate scientific advances into commercial and societal impact. 

From Opportunity to Ecosystem Development 

Across the GCC, governments are strengthening biotechnology capabilities through targeted strategies and investments. Saudi Arabia’s National Biotechnology Strategy, the UAE’s life sciences hubs and Qatar’s focus on precision medicine and biomedical research illustrate a shared commitment to advancing innovation and integrating new avenues for economic growth. 

However, global competitiveness requires more than investment alone. Successful biotechnology ecosystems combine world-class research, access to capital, supportive regulation, industry collaboration and specialised talent. Countries that effectively align these elements will be best positioned to unlock value from one of the world’s fastest-growing industries. 

Building a Biotechnology Ecosystem in Qatar 

In Qatar, biotechnology development is closely aligned with the ambitions of Qatar National Vision 2030, which places health and human development at the centre of the country’s long-term growth strategy. 

The country has made sustained investments in research, healthcare and scientific infrastructure. Qatar has allocated approximately 0.5–0.7% of GDP to research and development in recent years and aims to increase this to 1.5% by 2030. At the same time, healthcare expenditure is projected to grow from approximately USD 7 billion in 2025 to USD 12.5 billion by 2030, supporting the continued development of an innovation-driven healthcare ecosystem. 

This ambition is underpinned by a strong institutional foundation. Organisations such as Qatar Foundation, the Qatar Biomedical Research Institute (QBRI), the Qatar Environment and Energy Research Institute (QEERI), Sidra Medicine and leading academic institutions are contributing to scientific discovery, clinical development and talent cultivation. 

Precision Medicine as a Strategic Differentiator 

One area where Qatar has established particular strength is precision medicine and genomics. National initiatives, including the Qatar Precision Health Institute (QPHI), which is responsible for Qatar Biobank and the Qatar Genome Programme have collectively advanced population-scale research, with more than 40,000 Qatari and Arab genomes sequenced, creating one of the region's most comprehensive genomic datasets. 

These initiatives are supporting disease-specific research, enabling more personalised healthcare approaches and fostering opportunities for scientific collaboration and innovation. 

Looking Ahead 

As biotechnology becomes increasingly central to future economic competitiveness, the countries that successfully connect research excellence, investment capital and commercialisation capabilities will define the next generation of global biotech hubs.  

The countries that succeed in building these integrated ecosystems will not only strengthen healthcare and food security outcomes but also unlock new engines of innovation, competitiveness and economic growth. Through continued investment in research infrastructure, precision health and international collaboration, Qatar is helping lay the foundations for a dynamic biotechnology ecosystem and contributing to the next chapter of global biotechnology innovation.